SLS - Sellas Life Sciences Group / On Buy Rating

Offering geplant

www.sellaslifesciences.com/investors/news/...ing/default.aspx

20 Mio. $ Offering

• 7,22 Mio. neue Aktien zu je 2,77$
  

www.sellaslifesciences.com/investors/news/...ing/default.aspx

9 Mio. $ Offering

• 12 Mio. neue Aktien zu je 0,75$
  

www.sellaslifesciences.com/investors/news/...ing/default.aspx

https://valueinvestorsclub-com.translate.goog/idea/SELLAS_LIFE_SCIENCES_GROUP_I/9286565496?_x_tr_sl=en&_x_tr_tl=de&_x_tr_hl=de&_x_tr_pto=wapp

https://www.wallstreet-online.de/diskussion/1177530-1-10/sellas-life-sciences-group-ehemals-galena-biopharma#beitrag_76800636

ir.sellaslifesciences.com/news/...eloid-Leukemia/default.aspx

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

October 28, 2026

- Reaching the Pre-Specified 80^th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -

- Company to Report Topline Primary Endpoint Results this Quarter -

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) has reached the pre-specified 80^th event (number of deaths), triggering the final analysis of the study.

The REGAL trial is an event-driven overall survival study, and with the occurrence of the 80^th event, SELLAS will proceed with database lock, unblinding of the study data, and statistical analysis of the primary endpoint data. Upon completion of this analysis, the Company will announce this quarter the preliminary topline primary endpoint results from the trial in accordance with the study’s pre-specified statistical analysis plan (SAP).

“Reaching the 80^th event represents a critical milestone in the REGAL trial,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “AML remains an area of significant unmet need, particularly for patients in second complete remission with limited treatment options. With this pivotal study now advancing to final analysis, we look forward to evaluating the data, as positive results could position GPS as the first- and best-in-class novel immunotherapeutic option for these patients. On behalf of everyone at SELLAS, my sincerest appreciation goes out to all the physicians, nurses, study teams and, importantly, the participating patients and their families for their immense contributions in advancing the REGAL study. Our commitment to delivering hope to the AML community has never been stronger.”